SPAS(SH:603168) Shang Hai Zheng Quan Bao·2025-09-24 20:56Core Viewpoint - Zhejiang Shapuaisi Pharmaceutical Co., Ltd. announced the postponement of the investment project for the "Phase II Construction Project of Taizhou Women's and Children's Hospital Co., Ltd." to September 30, 2026, due to the cautious implementation of the project and the need to adjust the investment pace [6][9]. Group 1: Board Meeting - The sixth board meeting of Zhejiang Shapuaisi was held on September 24, 2025, with all nine directors present, and the meeting was deemed legal and effective [2][5]. - The board approved the proposal to waive the notification period for the meeting [3]. - The board also approved the proposal regarding the postponement of the fundraising project [3][11]. Group 2: Fundraising Project Details - The company raised a total of approximately RMB 317.99 million through a non-public stock issuance, with a net amount of RMB 308.24 million after deducting various fees [7]. - As of June 30, 2025, the company had used RMB 309.13 million of the raised funds [8]. - The remaining uninvested portion of the project will be funded by the company’s own funds [9][12]. Group 3: Reasons for Postponement - The postponement of the project is attributed to the company's cautious approach in managing its operations and overall fund usage, leading to a slower investment pace [9]. - The decision to extend the project timeline aims to enhance the efficiency of fund utilization [9]. Group 4: Compliance and Opinions - The postponement was reviewed and approved by the board and the audit committee, complying with relevant regulations [11][12]. - The sponsor institution, Shenwan Hongyuan Securities, confirmed that the necessary procedures were followed and had no objections to the postponement [12].